medwireNews: Treatment with the multikinase inhibitor cabozantinib is associated with better outcomes than everolimus therapy in patients with previously treated advanced renal cell carcinoma (RCC) and bone involvement, suggests a prespecified subgroup analysis of the phase III METEOR trial.
Median progression-free and overall survival were longer for the 77 patients with baseline bone metastases who were randomly assigned to receive daily cabozantinib 60 mg than for their 65 counterparts given everolimus 10 mg/day, at 7.4 versus 2.7 months and 20.1 versus 12.1 months, respectively, giving hazard ratios of 0.33 and 0.54.
And a higher proportion of cabozantinib-treated participants achieved an objective response, at 17%, compared with none of those in the everolimus group.
Writing in the Journal of Clinical Oncology, Bernard Escudier (Institut Gustave Roussy, Villejuif, France) and study co-authors caution that their trial “was not powered for statistical testing of the subgroup analyses.”
But in light of the promising results, they believe “cabozantinib represents a good treatment option for this difficult-to-treat patient population.”
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group
See also: